Misonix CEO steps down Misonix (NSDQ:MSON) CEO Michael McManus, Jr. stepped down in early September, also leaving his post as director and chairman of the board of directors. Stavros Vizirgianakis, a member of the board of directors, is serving as the interim CEO while negotiating for a full-time position in the corner office. Vizirgiankis, who owned […]
Urologix Inc.
Urologix successor details dissolution plans
The successor to Urologix said today that it plans to completely dissolve during 2017, spelling the end for the Minneapolis-based urology device maker. Urologix, which made the Cooled ThermoTherapy and Prostiva RF devices to treat benign prostatic hyperplasia, licensed Prostiva from Medtronic (NYSE:MDT). But after running up a $2.8 million tab on its Twin Cities neighbor, Urologix couldn’t come up […]
Urologix sold to settle debt to Medtronic
Urologix Inc. (OCT:ULGX) yesterday said it sold almost all of its assets to a secured creditor, which then sold them to a private company that will operate the business as Urologix LLC. The remnants of Urologix Inc. were renamed 21st North Inc. The Minneapolis-based company, which makes the Cooled ThermoTherapy and Prostiva RF devices to treat benign […]
RIP former Evalve CEO Powell | Personnel Moves
GI Dynamics swaps CEOs | Personnel Moves
Urologix completes layoffs, announces preliminary results
Analyst speculates Smith & Nephew split | Medtech Wall Street news for the week of Mar. 31, 2014
Urologix still owes Medtronic $650k
Layoffs ahead as Urologix restructures
Iguana Healthcare Partners raises $54M investment fund | Wall Street Beat
New York-based lifesciences investment group Iguana Healthcare Partners filed an amended notice, reporting that the company has raised more than $53.5 million in pooled investment fund interests.
The funding, raised among 20 unnamed investors, will support Iguana’s interests in pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services and healthcare information technology.
Abiomed rebounds after 4% slide on Piper Jaffray downgrade | Wall Street Beat
Abiomed (NSDQ:ABMD) shares clawed back some of the nearly 4% lost yesterday as investors reacted to a downgrade by analysts at Piper Jaffray.
The Danvers, Mass.-based medical device company’s stock fell from a $17.20-per-share close April 8 to end yesterday at $16.52 per share, a more than 3.9% decline. ABMD shares were trading at $16.98 apiece as of about 11 this morning, however, up 2.8%.
